Biopromic

Biopromic is working to change the future of rapid, point-of-care diagnostics for the detection of infectious diseases. A spectrum of Biopromic's proprietary technologies allows for the development of simple-to-use and affordable tests for clinical and veterinary settings. Biopromic specializes in the production of ultra-sensitive monoclonal antibodies targeted primarily against carbohydrate antigens derived from bacteria and viruses. Biopromic also produces a wide range of bacterial antigens and their analogs. Biopromic is a privately held company established in 2006 in Poland. In 2017, Biopromic opened its new R&D facility at Karolinska Institutet Science Park in Stockholm, Sweden. www.biopromic.com